Insmed Incorporated (INSM) Financial Ratios
27 years of historical data (1999–2025) · Healthcare · Medical - Pharmaceuticals
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
36.92
↑+21% vs avg
5yr avg: 30.49
30Y Low0.4·High46.9
ROE
↓
-249.3%
-12% vs avg
5yr avg: -222.3%
30Y Low-461%·High195%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
INSM Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Insmed Incorporated currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $29.1B | $34.6B | $11.3B | $4.4B | $2.5B | $3.1B | $3.2B | $2.0B | $1.0B | $2.1B | $819M |
| Enterprise Value | $28.7B | $34.2B | $12.1B | $5.1B | $2.6B | $2.9B | $3.1B | $1.9B | $830M | $1.8B | $711M |
| P/E Ratio → | -21.35 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 48.06 | 57.12 | 31.14 | 14.26 | 10.02 | 16.20 | 19.76 | 14.80 | 102.57 | — | — |
| P/B Ratio | 36.92 | 46.87 | 39.69 | — | 27.95 | 7.44 | 11.78 | 7.72 | 4.84 | 5.75 | 5.30 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
INSM EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 56.35 | 33.23 | 16.62 | 10.44 | 15.65 | 18.98 | 14.13 | 84.42 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
INSM Profitability
Margins and return-on-capital ratios measuring operating efficiency
Insmed Incorporated earns an operating margin of -205.6%. Operating margins have expanded from -232.5% to -205.6% over the past 3 years, signaling improving operational efficiency. A negative ROE of -249.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 79.7% | 79.7% | 76.4% | 78.5% | 77.5% | 76.6% | 75.7% | 82.3% | 75.4% | — | — |
| Operating Margin | -205.6% | -205.6% | -241.5% | -232.5% | -186.4% | -199.0% | -161.3% | -172.4% | -3124.9% | — | — |
| Net Profit Margin | -210.5% | -210.5% | -251.2% | -245.6% | -196.3% | -230.6% | -178.9% | -186.4% | -3297.2% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -249.3% | -249.3% | -320.2% | — | -193.2% | -126.7% | -109.4% | -108.2% | -113.9% | -74.7% | -75.6% |
| ROA | -59.5% | -59.5% | -54.5% | -50.2% | -33.2% | -42.6% | -38.2% | -37.8% | -60.8% | -55.0% | -59.3% |
| ROIC | -141.8% | -141.8% | -91.9% | -183.1% | -137.8% | -124.0% | -124.6% | -175.5% | -706.9% | -345.0% | -258.4% |
| ROCE | -70.8% | -70.8% | -62.0% | -55.2% | -35.5% | -42.0% | -39.8% | -39.8% | -65.2% | -60.2% | -63.7% |
INSM Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $510M exceeds total debt of $46M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | 4.60 | — | 13.39 | 1.49 | 1.47 | 1.52 | 1.52 | 0.15 | 0.35 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.63 | 2.66 | — | 1.18 | -0.25 | -0.46 | -0.35 | -0.86 | -0.90 | -0.70 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -10.34 | -8.69 | -17.29 | -9.27 | -8.97 | -8.49 | -12.07 | -31.89 | -49.57 |
Net cash position: cash ($510M) exceeds total debt ($46M)
INSM Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Insmed Incorporated's current ratio of 3.83x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.12x to 3.83x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.83 | 3.83 | 5.45 | 4.12 | 6.69 | 6.19 | 5.24 | 6.51 | 6.51 | 8.72 | 6.02 |
| Quick Ratio | 3.54 | 3.54 | 5.12 | 3.75 | 6.33 | 5.70 | 4.83 | 6.18 | 6.42 | 8.72 | 6.02 |
| Cash Ratio | 3.05 | 3.05 | 4.82 | 3.46 | 6.04 | 5.30 | 4.48 | 5.72 | 6.21 | 8.54 | 5.81 |
| Asset Turnover | — | 0.27 | 0.18 | 0.23 | 0.15 | 0.15 | 0.21 | 0.18 | 0.02 | — | — |
| Inventory Turnover | 0.93 | 0.93 | 0.87 | 0.79 | 0.79 | 0.66 | 0.80 | 0.86 | 0.34 | — | — |
| Days Sales Outstanding | — | 84.78 | 52.20 | 49.26 | 44.20 | 47.16 | 36.77 | 51.44 | 204.67 | — | — |
INSM Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Insmed Incorporated does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $199M | $164M | $140M | $123M | $112M | $98M | $85M | $77M | $67M | $62M |
Peer Comparison
Compare INSM with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 INSMYou | $29B | -21.4 | — | — | 79.7% | -205.6% | -249.3% | -141.8% | — |
 RARE | $3B | -4.4 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 ALNY | $40B | 130.0 | 71.9 | 86.9 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 BMRN | $11B | 30.3 | 16.0 | 14.5 | 77.1% | 16.6% | 5.9% | 7.4% | 1.0 |
 SRPT | $2B | -3.2 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 IONS | $13B | -32.3 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 ACAD | $4B | 9.4 | 25.6 | 35.0 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PRAX | $8B | -25.1 | — | — | — | — | -45.8% | -65.0% | — |
 ARWR | $11B | -6486.9 | 91.8 | 70.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 KRYS | $9B | 42.2 | 47.8 | 45.1 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 FOLD | $4B | -80.5 | 140.6 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 27 years · Updated daily
Full INSM Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See INSM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INSM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare INSM vs RARE
Side-by-side business, growth, and profitability comparison vs Ultragenyx Pharmaceutical Inc..
Start ComparisonINSM — Frequently Asked Questions
Quick answers to the most common questions about buying INSM stock.
What is Insmed Incorporated's P/E ratio?
Insmed Incorporated's current P/E ratio is -21.4x. The historical average is 0.8x.
What is Insmed Incorporated's ROE?
Insmed Incorporated's return on equity (ROE) is -249.3%. The historical average is -134.5%.
Is INSM stock overvalued?
Based on historical data, Insmed Incorporated is trading at a P/E of -21.4x. Compare with industry peers and growth rates for a complete picture.
What are Insmed Incorporated's profit margins?
Insmed Incorporated has 79.7% gross margin and -205.6% operating margin.